<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039975</url>
  </required_header>
  <id_info>
    <org_study_id>A5159</org_study_id>
    <secondary_id>10959</secondary_id>
    <secondary_id>ACTG A5159</secondary_id>
    <secondary_id>AACTG A5159</secondary_id>
    <nct_id>NCT00039975</nct_id>
  </id_info>
  <brief_title>Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers</brief_title>
  <official_title>Evaluation of Potential Pharmacokinetic Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Diltiazem CD and amlodipine are drugs used to treat heart disease and high blood pressure.&#xD;
      The purpose of this study is to find out if these drugs interact with the anti-HIV drugs&#xD;
      indinavir and ritonavir. The study will also look at the safety of taking the study drugs&#xD;
      together.&#xD;
&#xD;
      Heart disease and high blood pressure are major health concerns for people with HIV. Standard&#xD;
      treatment for these illnesses often includes calcium channel blockers (CCBs). There is a&#xD;
      potential for significant drug interactions between CCBs and HIV protease inhibitors (PIs)&#xD;
      that may influence the dosing, monitoring, and choosing of CCBs and PIs when used in people&#xD;
      infected with HIV. This study will examine the drug interactions between 2 commonly used CCBs&#xD;
      and the PI combination indinavir and ritonavir (IDV/RTV). This information should help&#xD;
      doctors choose the appropriate treatment for high blood pressure or heart disease in people&#xD;
      taking PIs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic cardiovascular disease and hypertension occur in persons with HIV infection, and the&#xD;
      incidence and prevalence may increase over time as the infected population ages. Standard&#xD;
      pharmacologic interventions for these illnesses often include calcium channel blockers&#xD;
      (CCBs). Many of the calcium channel blockers are metabolized by cytochrome P450 3A4 (CYP&#xD;
      3A4), which is inhibited by some protease inhibitors (PIs). Thus, there is potential for&#xD;
      clinically significant interactions between CCBs and PIs. The presence of significant&#xD;
      drug-drug interactions may influence the dosing, monitoring, and choosing of CCBs and/or PIs&#xD;
      when used in persons with HIV infection. Because of the potential concomitant use of CCBs&#xD;
      with the PI combination IDV/RTV, this study will evaluate bi-directional drug-drug&#xD;
      interactions between 2 commonly used CCBs and IDV/RTV. This information should assist&#xD;
      clinicians in choosing the appropriate CCBs to treat hypertension or cardiovascular disease&#xD;
      in persons taking PIs.&#xD;
&#xD;
      Patients are randomized to 1 of the following 2 arms:&#xD;
&#xD;
      Arm A: diltiazem CD interaction with IDV and RTV. Arm B: amlodipine interaction with IDV and&#xD;
      RTV. From Days 1 to 7, patients take diltiazem CD (Arm A) or amlodipine (Arm B). Plasma is&#xD;
      collected for PK over a 24-hour period beginning on Day 7. From Days 8 to 19, patients stop&#xD;
      taking their assigned CCB and take IDV and RTV. Plasma is collected for PK over a 12-hour&#xD;
      period on Day 19. From Days 20 to 26, patients continue to take IDV and RTV and add diltiazem&#xD;
      CD (Arm A) or amlodipine (Arm B). Patients stop all 3 drugs after the last dose on Day 26.&#xD;
      Plasma is collected for PK for a 24-hour period beginning on Day 26. Blood work, liver and&#xD;
      kidney function tests, urinalysis, and an electrocardiogram (EKG) are performed at some&#xD;
      visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>32</enrollment>
  <condition>HIV Infections</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem HCl</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients may be eligible for this study if they:&#xD;
&#xD;
          -  Are HIV-negative.&#xD;
&#xD;
          -  Are between the ages of 18 and 60.&#xD;
&#xD;
          -  Agree not to become pregnant or to impregnate and to use an acceptable form of&#xD;
             contraception while receiving study drugs and for 1 month after stopping study drugs.&#xD;
             Patients who are not of reproductive potential are eligible without the contraception&#xD;
             requirement.&#xD;
&#xD;
          -  Are within 30 percent of ideal body weight.&#xD;
&#xD;
          -  Weigh at least 110 lbs.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients may not be eligible for this study if they:&#xD;
&#xD;
          -  Have a history of any illness that requires current medical therapy.&#xD;
&#xD;
          -  Have a history of any kidney disorder.&#xD;
&#xD;
          -  Have any medical condition that, in the opinion of the investigator, would interfere&#xD;
             with the study.&#xD;
&#xD;
          -  Are pregnant or breast-feeding.&#xD;
&#xD;
          -  Use certain drugs within 14 days prior to study entry.&#xD;
&#xD;
          -  Are allergic or sensitive to study drugs.&#xD;
&#xD;
          -  Use drugs or alcohol in a way which, in the opinion of the investigator, would&#xD;
             interfere with the study.&#xD;
&#xD;
          -  Have any abnormality on electrocardiogram within 21 days prior to study entry.&#xD;
&#xD;
          -  Participate in any investigational drug studies within 21 days prior to study entry&#xD;
             and during study.&#xD;
&#xD;
          -  Are unable to participate in pharmacokinetic visits.&#xD;
&#xD;
          -  Are unable to understand or follow the fluid intake requirement during the periods of&#xD;
             IDV/RTV administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marshall Glesby</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Univ Med Ctr</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>943055107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Health Sciences Ctr</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univ (St. Louis)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1455</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Yunis NA, Stone VE. Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jun 1;18(2):145-54. Review.</citation>
    <PMID>9637579</PMID>
  </reference>
  <reference>
    <citation>Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, Daley J. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998 May 2;351(9112):1328.</citation>
    <PMID>9643798</PMID>
  </reference>
  <reference>
    <citation>Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Cadrobbi P. Indinavir and systemic hypertension. AIDS. 2001 Apr 13;15(6):805-7.</citation>
    <PMID>11371700</PMID>
  </reference>
  <reference>
    <citation>Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis. 2000 Sep;31(3):787-97. Epub 2000 Oct 4. Review.</citation>
    <PMID>11017831</PMID>
  </reference>
  <results_reference>
    <citation>Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, Grosskopf N, Zolopa AR, Gerber JG; Adult AIDS Clinical Trials Group A5159 Protocol Team. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther. 2005 Aug;78(2):143-53.</citation>
    <PMID>16084849</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 18, 2002</study_first_submitted>
  <study_first_submitted_qc>June 19, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2002</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Interactions</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Indinavir</keyword>
  <keyword>Calcium Channel Blockers</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Diltiazem</keyword>
  <keyword>Amlodipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

